DIGESTIVE AND LIVER DISEASE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2023-04-17 ms1000002026392296 来自甘肃省

偏重的研究方向：肝细胞癌;肝病
经验分享：请问大家，这个杂志接受meta吗

51 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2023-07-18 ms2000002077912665 来自北京

偏重的研究方向：消化道;肿瘤
经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？

60 0

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2022-10-09 Eugene Deng

请问这个杂志可以共一吗

65 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2021-08-24 12213dcbm39暂无昵称

审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0
偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病
经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。

0 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2022-05-18 148ba275m67暂无昵称

我也是想请教大家，怎么一直在初始投稿状态

63 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2022-06-06 ms1000000947456498

偏重的研究方向：基础研究
经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业

67 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2022-04-27 282597582

偏重的研究方向：肝细胞癌;临床研究
经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么

62 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2022-10-25 小可爱的

能接受生信➕验证吗

37 0

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2022-10-18 ms3000000590360295

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：不错

29 0

[GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2148637, encodeId=1682214863e02, content=偏重的研究方向：消化道;肿瘤 经验分享：这个杂志投稿以后貌似看不到状态，只能等邮件通知？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90305421914, createdName=ms2000002077912665, createdTime=Tue Jul 18 18:02:42 CST 2023, time=2023-07-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010931, encodeId=1736101093195, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:3300.0 偏重的研究方向：消化系统良性疾病;急性胰腺炎;肝病 经验分享：最近接收一篇，7月13投稿，8.3第一次返修，8.14第二次返修，8.20接收。这个杂志效率很高。以前全部都不收版面费，现在可选择OA付版面费3300美刀或者不交版面费（但是得接收后1年才能online）。投稿后一直是初始的时间状态不会显示under review，如果一个礼拜没拒稿基本就是送审了，耐心等待即可。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=12213dcbm39暂无昵称, createdTime=Tue Aug 24 11:35:45 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220580, encodeId=335a12205808f, content=我也是想请教大家，怎么一直在初始投稿状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=889e5325563, createdName=148ba275m67暂无昵称, createdTime=Wed May 18 00:25:23 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224667, encodeId=9bb1122466e19, content=偏重的研究方向：基础研究 经验分享：5月5日投稿，5月15日under review，今天6月6日也还没有消息，好急呀，赶着明年毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1676564630, createdName=ms1000000947456498, createdTime=Mon Jun 06 08:02:30 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215059, encodeId=2d071215059a6, content=偏重的研究方向：肝细胞癌;临床研究 经验分享：24号投稿，26号分配的稿件号，500➕，不知道多久能送审？有知道的小伙伴们么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7e2868906, createdName=282597582, createdTime=Wed Apr 27 16:37:43 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096136, encodeId=1e8920961367b, content=能接受生信➕验证吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210917/e46ee6b8004843a6bc90b491c388dbde/b538a1ea6c4749eda3c6632203fc3886.jpg, createdBy=40b95313759, createdName=小可爱的, createdTime=Tue Oct 25 21:49:43 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094401, encodeId=d22a209440106, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=614a8379235, createdName=ms3000000590360295, createdTime=Tue Oct 18 12:17:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=)]

2016-10-10 紫微愿

审稿速度:6.0 | 投稿命中率:50.0
经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。

401 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务